Context Therapeutics Inc (CNTX) Actualités

Form 8-K - Current report

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”...

Context Therapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq:...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone...

Form 8-K - Current report

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights...

Form 8-K - Current report